June 2020 in “Zenodo (CERN European Organization for Nuclear Research)” The DNMT3B -579G>T polymorphism may increase the risk of colorectal cancer.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
5 citations
,
May 2020 in “Life science alliance” Removing integrin α3β1 from hair stem cells lowers skin tumor growth by affecting CCN2 protein levels.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
January 2014 in “IOSR journal of pharmacy” Adalimumab can cause complete hair loss in rare cases.
January 2007 in “xPharm: The Comprehensive Pharmacology Reference” July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
36 citations
,
September 1999 in “Journal of Cell Science” Basonuclin may help control ribosomal RNA gene activity in skin cells.
Clitocybin A can promote hair growth by increasing cell proliferation.
76 citations
,
June 2018 in “EMBO Reports” YAP and TAZ proteins are necessary for the development of two types of skin cancer.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
February 2018 in “The Journal of Sexual Medicine” DA-9401 protects against hair loss, improves organ function, and prevents infertility caused by finasteride.
20 citations
,
October 2005 in “Archives of Dermatological Research”
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
May 2023 in “International journal of molecular sciences” The ABCA4 gene protects hair follicle stem cells from toxic vitamin A byproducts.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
17 citations
,
May 2018 in “PeerJ” VB-1, a natural compound, may promote hair growth by enhancing a key cell growth pathway.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
April 2018 in “Journal of Investigative Dermatology” Basonuclin 1 (BNC1) helps skin cells multiply and move, which is crucial for wound healing.
October 2021 in “The Egyptian Journal of Hospital Medicine” Alopecia areata causes patchy hair loss and involves immune system disruptions.
85 citations
,
June 2017 in “Journal of Investigative Dermatology” Blimp1 is crucial for hair follicle growth and skin health.
2 citations
,
January 1989 Tay syndrome is a unique genetic disorder causing skin, hair, and developmental issues.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.